Medicamen Biotech Ltd vs Titan Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Medicamen Biotech Ltd is ₹ 257.95 as of 04 May 10:01 . The P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 yearsThe P/E Ratio of Titan Biotech Ltd changed from 5.1 on March 2021 to 16.2 on March 2025 . This represents a CAGR of 26.01% over 5 years The Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 yearsThe Market Cap of Titan Biotech Ltd changed from ₹ 153.33 crore on March 2021 to ₹ 348.36 crore on March 2025 . This represents a CAGR of 17.84% over 5 years The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The revenue of Titan Biotech Ltd for the Dec '25 is ₹ 57.76 crore as compare to the Sep '25 revenue of ₹ 55.68 crore. This represent the growth of 3.74% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The ebitda of Titan Biotech Ltd for the Dec '25 is ₹ 12.09 crore as compare to the Sep '25 ebitda of ₹ 10.65 crore. This represent the growth of 13.52% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The net profit of Titan Biotech Ltd changed from ₹ 5.7 crore to ₹ 7.87 crore over 7 quarters. This represents a CAGR of 20.24% The Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 yearsThe Dividend Payout of Titan Biotech Ltd changed from 4.31 % on March 2021 to 9.04 % on March 2025 . This represents a CAGR of 15.97% over 5 years .

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

About Titan Biotech Ltd

Titan Biotech Limited, the New Delhi based company is into manufacture of Biological Peptones, Extracts and Dehydrated Culture media which are very conducive for the growth of micro organisms.
They are primarily used in the development and growth of micro organisms in clinical diagnosis production of vaccines antibiotics antisera etc, Checking the sensitivity of antibiotics in pharmaceutical industry, checking the bacterial contamination in food & water, tissue culture laboratories and in the departments of microbiology & botony in medical colleges/universities. The company uses Meat, Bile, Pancreatic, Liver, Blood, Brain, Heart and other parts of animals sourced from slaughter house and other vegetable products like soya, casein etc. converting them into free flowing powder to produce Peptones, Extracts and Hydrolysates which are further used in manufacturing of Dehydrated Culture Media and as raw material in pharma health products and other industries.

FAQs for the comparison of Medicamen Biotech Ltd and Titan Biotech Ltd

Which company has a larger market capitalization, Medicamen Biotech Ltd or Titan Biotech Ltd?

Market cap of Medicamen Biotech Ltd is 343 Cr while Market cap of Titan Biotech Ltd is 2,049 Cr

What are the key factors driving the stock performance of Medicamen Biotech Ltd and Titan Biotech Ltd?

The stock performance of Medicamen Biotech Ltd and Titan Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Biotech Ltd and Titan Biotech Ltd?

As of May 4, 2026, the Medicamen Biotech Ltd stock price is INR ₹253.3. On the other hand, Titan Biotech Ltd stock price is INR ₹496.0.

How do dividend payouts of Medicamen Biotech Ltd and Titan Biotech Ltd compare?

To compare the dividend payouts of Medicamen Biotech Ltd and Titan Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.